Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
Moodys
Medtronic
Cipla
Chubb
Boehringer Ingelheim
Baxter
McKesson

Generated: August 18, 2018

DrugPatentWatch Database Preview

Bayer Healthcare Company Profile

« Back to Dashboard

Summary for Bayer Healthcare
International Patents:163
US Patents:4
Tradenames:22
Ingredients:12
NDAs:28
Patent Litigation for Bayer Healthcare: See patent lawsuits for Bayer Healthcare

Drugs and US Patents for Bayer Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc CLARITIN HIVES RELIEF REDITAB loratadine TABLET, ORALLY DISINTEGRATING;ORAL 020704-003 Nov 19, 2003 OTC Yes Yes ➤ Sign Up ➤ Sign Up
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;IV (INFUSION) 209936-001 Sep 14, 2017 RX Yes Yes RE46856 ➤ Sign Up Y Y ➤ Sign Up
Bayer Healthcare Llc MYCELEX-7 COMBINATION PACK clotrimazole CREAM, TABLET;TOPICAL, VAGINAL 020389-002 Jun 23, 1994 DISCN No No ➤ Sign Up ➤ Sign Up
Bayer Healthcare Llc CHLOR-TRIMETON chlorpheniramine maleate TABLET, EXTENDED RELEASE;ORAL 007638-002 Approved Prior to Jan 1, 1982 OTC Yes Yes ➤ Sign Up ➤ Sign Up
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;IV (INFUSION) 209936-001 Sep 14, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up
Bayer Healthcare Llc GYNE-LOTRIMIN 3 clotrimazole TABLET;VAGINAL 020525-001 Jul 29, 1996 DISCN Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Bayer Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Healthcare Llc MYCELEX clotrimazole CREAM;TOPICAL 018183-001 Approved Prior to Jan 1, 1982 3,705,172 ➤ Sign Up
Bayer Healthcare Llc CLARITIN loratadine TABLET;ORAL 019658-002 Nov 27, 2002 4,659,716*PED ➤ Sign Up
Bayer Healthcare Llc CLARITIN-D 24 HOUR loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 020470-002 Nov 27, 2002 4,863,931*PED ➤ Sign Up
Bayer Healthcare Llc CLARITIN loratadine SYRUP;ORAL 020641-002 Nov 27, 2002 6,132,758 ➤ Sign Up
Bayer Healthcare Llc ZEGERID OTC omeprazole; sodium bicarbonate CAPSULE;ORAL 022281-001 Dec 1, 2009 6,489,346 ➤ Sign Up
Bayer Healthcare Llc CLARITIN loratadine SYRUP;ORAL 020641-002 Nov 27, 2002 4,863,931*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for BAYER HEALTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 20 mg/1100 mg ➤ Subscribe 2010-04-20

Non-Orange Book US Patents for Bayer Healthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,514,520 Stabilized antihistamine syrup ➤ Sign Up
8,129,386 Fused azole-pyrimidine derivatives ➤ Sign Up
6,939,550 Stabilized antihistamine syrup ➤ Sign Up
8,466,283 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Bayer Healthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/005 United Kingdom ➤ Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
01C/013 Belgium ➤ Sign Up PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
C/GB11/015 United Kingdom ➤ Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
C/GB11/013 United Kingdom ➤ Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
C0004 France ➤ Sign Up PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
C/GB01/012 United Kingdom ➤ Sign Up PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Cipla
Baxter
McKinsey
Healthtrust
Medtronic
Moodys
Mallinckrodt
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.